Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib

Triple-negative breast cancer (TNBC) accounts for 20% of all molecular subtypes of breast cancer. Neither endocrine nor anti-HER2 molecular targeting treatment yield promising results. At present, epidermal growth factor receptor (EGFR) inhibitor, as a single agent, is unable to obtain encouraging r...

Full description

Saved in:
Bibliographic Details
Published in:Oncol Rep
Main Authors: WANG, XINZHAO, SONG, HONGKUAN, YU, QIAN, LIU, QI, WANG, LEILEI, LIU, ZHAOYUN, YU, ZHIYONG
Format: Artigo
Language:Inglês
Published: D.A. Spandidos 2015
Subjects:
Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4306269/
https://ncbi.nlm.nih.gov/pubmed/25501339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2014.3665
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items